Devi G. Nair, M.D., FHRS, director of cardiac electrophysiology, St. Bernards Heart and Vascular Center, Jonesboro, Ark., was an investigator in the PINNACLE FLX clinical trial for the Boston Scientific Watchman FLX left atrial appendage (LAA) occluder device.
The newest iteration of the Watchman was cleared by the U.S. Food and Drug Administration (FDA) in July 2020. Read more about the Watchman FLX
The transcatheter implant is used in close the LAA, a pouch that forms part of the left atrium. The LAA is implicated in the formation of blood clots that cause stroke in patients with atrial fibrillation (AF). The Watchman FLX is indicated to reduce the risk of stroke in patients with non-valvular AF (NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage.
Nair is currently involved with another trial of the Watchman FLX, OPTION FLX trial, which is examining the use of LAA occlusion in post-ablation patients.
Nair is also chairman for the Heart Rhythm Society (HRS) member engagement sub-committee and is a board member of the Arkansas chapter of the American College of Cardiology (ACC).
Watch Nair in this interview — VIDEO: Impact of COVID-19 on Electrophysiology Programs
Recent Videos View all 613 items
Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in the mitral valve prior to taking on his current role where he oversees Abbott's advancements in transcatheter valve technologies.
He explains some of the evolution in the industry as surgical repairs now are offered side-by-side with transcatheter valve replacement and repair technologies. He notes that the number of heart valve patients being treated has increased with the introduction of transcatheter technologies, and that surgical volumes have not been impacted as much as people thing because more patients overall are now being treated for valve disease.
Related Transcatheter Valve Trends Content:
TAVR Expected to See Rapid Growth in Next 5 years
FDA Approves TAVR for Low-risk Patients Creates A Paradigm Shift in Cardiology
VIDEO: The Expansion of TAVR Following the FDA Clearing its Use in All Patients — Interview with Torsten Vahl, M.D.
VIDEO: Overview of the TAVR Program at Tufts Medical Center — Interview with Andrew Weintraub, M.D.
VIDEO: Tracking Transcatheter Valve Outcomes in the STS-ACC TVT Registry — John Carroll, M.D.
VIDEO: Overview of University of Colorado Structural Heart Program — Interview with John Carroll, M.D., Robert Quaife, M.D., and James Chen, Ph.D.
VIDEO: Abbott Structural Heart Technology Advances in 2021 — Interview with Neil Moat, MBBS
An example of the Acutus Medical AcQMap High Resolution Imaging and Mapping System to guide electrophysiology (EP) cardiac ablations. The electrical mapping of the heart shows irregular atrial fibrillation (AFib) prior to an ablation.
The system uses a basket catheter with 48 electrodes combined with 48 tiny ultrasound transducers. The basket can be manually rotated around inside the atrium to rapidly “paint” a very accurate combined electro- and anatomical map simultaneously in about five minutes. Conventional EP mapping systems can take 20 minutes or longer to complete the mapping process. The electrodes do not need to contact the walls of the heart because the vendor said they can detect the electrical field created by cardiac contractions. The system has both FDA and European CE mark approvals.
Related EP Mapping Content:
FDA Clears Second-Generation AcQMap 3D EP Imaging and Mapping Catheter
What is New in Electrophysiology Technologies
Acutus Gains European CE Mark for Suite of Next Generation EP Products
New Technologies to Improve Atrial Fibrillation Ablation
Identifying Hubs of Re-entry Driving Persistent Atrial Fibrillation May Improve Treatment
Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how his center performs transcaval transcatheter aortic valve replacement (TAVR) access for patients who have suboptimal abdominal aortic and femoral vascular anatomy. Transcaval access was pioneered at Henry Ford Hospital and involves using femoral vein access and then using a surgical radio frequency cutter to bore a hole from the interior venacava into the aorta to allow the TAVR delivery catheter to path through.
This procedure was developed to enable more patients to receive TAVR via the preferred femoral access route. Some patients are not candidates for femoral artery access because of calcified lesions and heart atherosclerotic plaque, which narrows the vessel lumen, and makes it difficult to thread catheters through. The transcaval access technique can bypass the restricted arteries or heavy calcified plaques to still enable a minimally invasive procedure without the need for surgery.
This video was produced in partnership from Henry Ford Hospital.
Related Transcaval TAVR Content:
VIDEO: Transcaval Access in TAVR Procedures — Interview with Adam Greenbaum, M.D.
How to Perform Transcaval TAVR Access
VIDEO: Walk Through of the Henry Ford Hospital Structural Heart Cath Lab
Study Deems Transcaval Valve Replacement Pioneered at Henry Ford Hospital Successful
First Transcaval Aortic Valve Replacement Performed in Europe
Additional articles and videos on Henry Ford Hospital
Find more structural heart technology content
Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical engineering, University of Washington, Seattle, explains his department's development of engineered heart tissue that can beat. The "heart or organ in a dish" technology allows cardiac myocytes to be tested in a lab with various drugs or other influences to see what the impact would be on the heart.
This technology developed at UW was sent to the International Space Station in 2020 to help evaluate the impact of zero-gravity on the heart. This research plays a critical role in understanding the impact on the human heart in long-duration space flights to places like Mars or beyond.
The bioengineered tissue is the length of a couple grains of rice set between two posts so the tightening and stretching of cardiac muscles can be measured.
Read more details in the article Tiny Beating Hearts Created With Stem Cells at the University of Washington.
Sponsored Videos View all 41 items
With Intellispace Enterprise Edition as the foundation, Philips Healthcare is connecting facilities and service areas within enterprises, while developing standards-based interoperability that preserves customers' investments and best of breed systems.
Perwaiz Meraj, M.D., FACC, FSCAI, director of interventional cardiology, assistant professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health System discusses the importance of hemodynamic support to safely perform a percutaneous coronary intervention (PCI) with prior coronary artery bypass graft (CABG) surgery and comorbidities. Learn more at ProtectedPCI.com/DAIC.
Related Impella Video Content:
VIDEO: Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device — Interview with William O'Neill, M.D.
VIDEO: The Door-to-Unloading (DTU) STEMI Safety and Feasibility Trial — Interview with Navin Kapur, M.D.
VIDEO: Cardiogenic Shock Case with Impella CP Support — Case study with Michael Amponsah, M.D.,
William O'Neill, M.D., highlights best practice protocols based on Impella Quality database and real-world evidence showing improved outcomes in cardiogenic shock. Learn more at ProtectedPCI.com/DAIC
Related Impella Video Content:
VIDEO: Complex PCI Involving Prior CABG and Comorbidities — Interview with Perwaiz Meraj, M.D.
VIDEO: The Door-to-Unloading (DTU) STEMI Safety and Feasibility Trial — Interview with Navin Kapur, M.D.
VIDEO: Cardiogenic Shock Case with Impella CP Support — Case study with Michael Amponsah, M.D.,
Mark Anderson, M.D., FACS, vice chair of cardiac surgery services and cardiothoracic surgeon at Hackensack University Medical Group, outlines a multi-disciplinary heart team approach in treament decision-making for patients in cardiogenic shock. Learn more at ProtectedPCI.com/DAIC.
Anderson discusses improving outcomes for patients in cardiogenic shock through the early use of mechanical circulatory support and the development of a shock protocol with the heart team. He outlines Hackensack University Medical Center’s multi-disciplinary, heart team approach in treatment decision-making for patients in cardiogenic shock. The team includes cardiac surgeons, interventional cardiologists, heart failure specialists and intensivists.
Conference Coverage View all 443 items
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at Cleveland Clinic, was the lead author on a followup study to the landmark WRAP-IT trial that showed the Tyrx bioresorbable antibacterial envelope was shown it significantly lower infection risk for patients who receive cardiac implantable electronic devices (CIED) and develop hematomas.[1]
The study results showed an 82% reduction in major infection among patients with hematoma in patients who had received the Tyrx. It is a antimicrobial envelope that is used to place implantable electrophysiology (EP) devices inside prior to closing the device pocket. While the envelope itself did not prevent hemotomas, as the rate was the same in the control group with out it, the Tyrx did lower infection rates in patients with hemotomas.
Read more in the article Tyrx Absorbable Antibacterial Envelope Effectively Reduces Infections in Cardiac Device Patients with Hematomas.
Reference:
One of the trends in cardiovascular information system (CVIS) and radiology PACS at the Healthcare Information Management Systems Society (HIMSS) 2021 conference was the deeper integration of third-party image analysis software and artificial intelligence (AI) into these systems. This eliminates software sitting on top of the CVIS or PACS, separate logins or needing to us a different screen or manually transferring information from the third-party app in into the final report.
A good example of this was Siemens Healthineers, which demonstrated a deep integration with Epsilon Imaging’s echocardiography strain imaging analysis software. The integration eliminates the need for a separate login to the software, and automated quantification and images are carried over directly into the syngo echo report.
Strain can be used to assess cardiac function more precisely than regular cardiac ultrasound exams. It has grown in its use for cardio-oncology programs, assessing a baseline cardiac function and the. Performing serial exams over the course of a cancer patient’s chemotherapy. Strain has seen growing interest and has been a hot topic the past couple years at the American Society of Echocardiography (ASE) meeting. Interest also has expanded greatly recently with reimbursement now available in the U.S.
Siemens said there also has been increased interest in strain this past year because it can show early indicators of cardiac issues in COVID-19 patients and can be used to help monitor COVID myocarditis patients.
Related Strain Echo and HIMSS Content:
VIDEO: An Overview of Echo Strain Imaging — Interview with Marielle Scherrer-Crosbie, M.D.
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
VIDEO: Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging — Interview with Federico Asch, M.D.
Assessing Cardiotoxicity Due to Cancer Therapy
Advances in CVIS and Enterprise iImaging at HIMSS 21
VIDEO: Cardiology AI Aggregates Patient Data and Enables Interactive Risk Assessments
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D., at HIMSS21
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D., at HIMSS21
The vendor MediCardia demonstrated smart software to aggregate cardiology patient data from numerous locations into one place at the 2021 Healthcare Information Management Systems Society (HIMSS) conference. This enables one dashboard view of the patient's relevant cardiac history, prior exams, imaging, ECGs, labs and procedures. It also uses artificial intelligence (AI) to pull key data elements about the patient to automatically create risk assessments based on current guidelines in a graphical format.
The interactive system also allows the cardiologist to adjust parameters in the patient risk score to immediately show the patient any impact on their score. This includes if they stopped smoking, began taking statins, etc. The dynamic graphics of the system are also designed to be more engaging with a patient during consultations, rather than plain white pages of reports.
MediCardia HeartChart is a cardiology-focused virtual care platform that serves as a unified and common interface for EHRs and remote technologies including wearables, consumer home medical devices, and implanted cardiac rhythm devices.
Related HIMSS CVIS and PACS Content:
Read about more advances in PACS and enterprise imaging at HIMSS 21.
VIDEO: Example of Epsilon Strain Imaging Deep Integration With Siemens CVIS
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D.
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D.
A new ultrasound imaging technology that may offer novel ways to diagnose and better understand cardiac diseases using dynamic blood flow imaging. This allows imaging of individual blood cells or contrast bubbles as they travel through the heart and vessels, showing detail in how the blood moves and swirls. These motions, including the formation of vortices, may offer new insight into different disease states and allow earlier diagnosis and a understand better when to intervene.
The examples shown in this short video are from Hitachi and GE Healthcare, both of which have highlighted this technology at the American Society of Echocardiography (ASE) annual meetings over the past four years.
Ultrasound vendors use different technology approaches, including vector flow imaging, particle imaging velocimetry and blood speckle tracking. All of them show small lines or arrows to indicate the direction the blood cells or bubbles are traveling, and color codes to indicate velocity. Some vendors offer quantification for some new measures of blood flow, but as of yet, there are no guidelines or standardized indexes as to what these numbers mean.
This technology has been discussed in research sessions at the IEEE and the ASE over the past several years. However, more research is needed to show the prognostic value of the technology. Research to date shows it is possible that the swirling of blood can indicate less efficient flow, which may have implications in the development of heart failure, pulmonary hypertension and advancement of valvular disease. In the coronary arteries, research has shown there may be a connection between sheer stresses and disrupted blood flow in the formation of plaques on artery walls.
Companies that have developed echo blood flow dynamics imaging on their ultrasound systems to date include Hitachi, GE Healthcare, Fujifilm, Mindray and BK Medical.
Read more about this technology from ASE 2021 in the article Development of Echo Blood Flow Dynamics Imaging.
Related Dynamic Blood Flow Echo Imaging Content:
Aurora St. Luke’s Medical Center in Milwaukee Adopts Latest Echocardiography Imaging Software
A Glimpse Into the Future of Cardiac Ultrasound
Analogic Introduces New Premium Cardiac Imaging Software for bk3500 Ultrasound System
Improving Stent Designs With Computational Fluid Dynamics
VIDEO: Editor's Choice of Most Innovative New Cardiac Ultrasound Technology at ASE 2017
Cath Lab View all 309 items
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at Cleveland Clinic, was the lead author on a followup study to the landmark WRAP-IT trial that showed the Tyrx bioresorbable antibacterial envelope was shown it significantly lower infection risk for patients who receive cardiac implantable electronic devices (CIED) and develop hematomas.[1]
The study results showed an 82% reduction in major infection among patients with hematoma in patients who had received the Tyrx. It is a antimicrobial envelope that is used to place implantable electrophysiology (EP) devices inside prior to closing the device pocket. While the envelope itself did not prevent hemotomas, as the rate was the same in the control group with out it, the Tyrx did lower infection rates in patients with hemotomas.
Read more in the article Tyrx Absorbable Antibacterial Envelope Effectively Reduces Infections in Cardiac Device Patients with Hematomas.
Reference:
One of the trends in cardiovascular information system (CVIS) and radiology PACS at the Healthcare Information Management Systems Society (HIMSS) 2021 conference was the deeper integration of third-party image analysis software and artificial intelligence (AI) into these systems. This eliminates software sitting on top of the CVIS or PACS, separate logins or needing to us a different screen or manually transferring information from the third-party app in into the final report.
A good example of this was Siemens Healthineers, which demonstrated a deep integration with Epsilon Imaging’s echocardiography strain imaging analysis software. The integration eliminates the need for a separate login to the software, and automated quantification and images are carried over directly into the syngo echo report.
Strain can be used to assess cardiac function more precisely than regular cardiac ultrasound exams. It has grown in its use for cardio-oncology programs, assessing a baseline cardiac function and the. Performing serial exams over the course of a cancer patient’s chemotherapy. Strain has seen growing interest and has been a hot topic the past couple years at the American Society of Echocardiography (ASE) meeting. Interest also has expanded greatly recently with reimbursement now available in the U.S.
Siemens said there also has been increased interest in strain this past year because it can show early indicators of cardiac issues in COVID-19 patients and can be used to help monitor COVID myocarditis patients.
Related Strain Echo and HIMSS Content:
VIDEO: An Overview of Echo Strain Imaging — Interview with Marielle Scherrer-Crosbie, M.D.
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
VIDEO: Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging — Interview with Federico Asch, M.D.
Assessing Cardiotoxicity Due to Cancer Therapy
Advances in CVIS and Enterprise iImaging at HIMSS 21
VIDEO: Cardiology AI Aggregates Patient Data and Enables Interactive Risk Assessments
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D., at HIMSS21
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D., at HIMSS21
The vendor MediCardia demonstrated smart software to aggregate cardiology patient data from numerous locations into one place at the 2021 Healthcare Information Management Systems Society (HIMSS) conference. This enables one dashboard view of the patient's relevant cardiac history, prior exams, imaging, ECGs, labs and procedures. It also uses artificial intelligence (AI) to pull key data elements about the patient to automatically create risk assessments based on current guidelines in a graphical format.
The interactive system also allows the cardiologist to adjust parameters in the patient risk score to immediately show the patient any impact on their score. This includes if they stopped smoking, began taking statins, etc. The dynamic graphics of the system are also designed to be more engaging with a patient during consultations, rather than plain white pages of reports.
MediCardia HeartChart is a cardiology-focused virtual care platform that serves as a unified and common interface for EHRs and remote technologies including wearables, consumer home medical devices, and implanted cardiac rhythm devices.
Related HIMSS CVIS and PACS Content:
Read about more advances in PACS and enterprise imaging at HIMSS 21.
VIDEO: Example of Epsilon Strain Imaging Deep Integration With Siemens CVIS
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D.
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D.
A new ultrasound imaging technology that may offer novel ways to diagnose and better understand cardiac diseases using dynamic blood flow imaging. This allows imaging of individual blood cells or contrast bubbles as they travel through the heart and vessels, showing detail in how the blood moves and swirls. These motions, including the formation of vortices, may offer new insight into different disease states and allow earlier diagnosis and a understand better when to intervene.
The examples shown in this short video are from Hitachi and GE Healthcare, both of which have highlighted this technology at the American Society of Echocardiography (ASE) annual meetings over the past four years.
Ultrasound vendors use different technology approaches, including vector flow imaging, particle imaging velocimetry and blood speckle tracking. All of them show small lines or arrows to indicate the direction the blood cells or bubbles are traveling, and color codes to indicate velocity. Some vendors offer quantification for some new measures of blood flow, but as of yet, there are no guidelines or standardized indexes as to what these numbers mean.
This technology has been discussed in research sessions at the IEEE and the ASE over the past several years. However, more research is needed to show the prognostic value of the technology. Research to date shows it is possible that the swirling of blood can indicate less efficient flow, which may have implications in the development of heart failure, pulmonary hypertension and advancement of valvular disease. In the coronary arteries, research has shown there may be a connection between sheer stresses and disrupted blood flow in the formation of plaques on artery walls.
Companies that have developed echo blood flow dynamics imaging on their ultrasound systems to date include Hitachi, GE Healthcare, Fujifilm, Mindray and BK Medical.
Read more about this technology from ASE 2021 in the article Development of Echo Blood Flow Dynamics Imaging.
Related Dynamic Blood Flow Echo Imaging Content:
Aurora St. Luke’s Medical Center in Milwaukee Adopts Latest Echocardiography Imaging Software
A Glimpse Into the Future of Cardiac Ultrasound
Analogic Introduces New Premium Cardiac Imaging Software for bk3500 Ultrasound System
Improving Stent Designs With Computational Fluid Dynamics
VIDEO: Editor's Choice of Most Innovative New Cardiac Ultrasound Technology at ASE 2017
Cardiac Imaging View all 269 items
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at Cleveland Clinic, was the lead author on a followup study to the landmark WRAP-IT trial that showed the Tyrx bioresorbable antibacterial envelope was shown it significantly lower infection risk for patients who receive cardiac implantable electronic devices (CIED) and develop hematomas.[1]
The study results showed an 82% reduction in major infection among patients with hematoma in patients who had received the Tyrx. It is a antimicrobial envelope that is used to place implantable electrophysiology (EP) devices inside prior to closing the device pocket. While the envelope itself did not prevent hemotomas, as the rate was the same in the control group with out it, the Tyrx did lower infection rates in patients with hemotomas.
Read more in the article Tyrx Absorbable Antibacterial Envelope Effectively Reduces Infections in Cardiac Device Patients with Hematomas.
Reference:
One of the trends in cardiovascular information system (CVIS) and radiology PACS at the Healthcare Information Management Systems Society (HIMSS) 2021 conference was the deeper integration of third-party image analysis software and artificial intelligence (AI) into these systems. This eliminates software sitting on top of the CVIS or PACS, separate logins or needing to us a different screen or manually transferring information from the third-party app in into the final report.
A good example of this was Siemens Healthineers, which demonstrated a deep integration with Epsilon Imaging’s echocardiography strain imaging analysis software. The integration eliminates the need for a separate login to the software, and automated quantification and images are carried over directly into the syngo echo report.
Strain can be used to assess cardiac function more precisely than regular cardiac ultrasound exams. It has grown in its use for cardio-oncology programs, assessing a baseline cardiac function and the. Performing serial exams over the course of a cancer patient’s chemotherapy. Strain has seen growing interest and has been a hot topic the past couple years at the American Society of Echocardiography (ASE) meeting. Interest also has expanded greatly recently with reimbursement now available in the U.S.
Siemens said there also has been increased interest in strain this past year because it can show early indicators of cardiac issues in COVID-19 patients and can be used to help monitor COVID myocarditis patients.
Related Strain Echo and HIMSS Content:
VIDEO: An Overview of Echo Strain Imaging — Interview with Marielle Scherrer-Crosbie, M.D.
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
VIDEO: Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging — Interview with Federico Asch, M.D.
Assessing Cardiotoxicity Due to Cancer Therapy
Advances in CVIS and Enterprise iImaging at HIMSS 21
VIDEO: Cardiology AI Aggregates Patient Data and Enables Interactive Risk Assessments
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D., at HIMSS21
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D., at HIMSS21
The vendor MediCardia demonstrated smart software to aggregate cardiology patient data from numerous locations into one place at the 2021 Healthcare Information Management Systems Society (HIMSS) conference. This enables one dashboard view of the patient's relevant cardiac history, prior exams, imaging, ECGs, labs and procedures. It also uses artificial intelligence (AI) to pull key data elements about the patient to automatically create risk assessments based on current guidelines in a graphical format.
The interactive system also allows the cardiologist to adjust parameters in the patient risk score to immediately show the patient any impact on their score. This includes if they stopped smoking, began taking statins, etc. The dynamic graphics of the system are also designed to be more engaging with a patient during consultations, rather than plain white pages of reports.
MediCardia HeartChart is a cardiology-focused virtual care platform that serves as a unified and common interface for EHRs and remote technologies including wearables, consumer home medical devices, and implanted cardiac rhythm devices.
Related HIMSS CVIS and PACS Content:
Read about more advances in PACS and enterprise imaging at HIMSS 21.
VIDEO: Example of Epsilon Strain Imaging Deep Integration With Siemens CVIS
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D.
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D.
A new ultrasound imaging technology that may offer novel ways to diagnose and better understand cardiac diseases using dynamic blood flow imaging. This allows imaging of individual blood cells or contrast bubbles as they travel through the heart and vessels, showing detail in how the blood moves and swirls. These motions, including the formation of vortices, may offer new insight into different disease states and allow earlier diagnosis and a understand better when to intervene.
The examples shown in this short video are from Hitachi and GE Healthcare, both of which have highlighted this technology at the American Society of Echocardiography (ASE) annual meetings over the past four years.
Ultrasound vendors use different technology approaches, including vector flow imaging, particle imaging velocimetry and blood speckle tracking. All of them show small lines or arrows to indicate the direction the blood cells or bubbles are traveling, and color codes to indicate velocity. Some vendors offer quantification for some new measures of blood flow, but as of yet, there are no guidelines or standardized indexes as to what these numbers mean.
This technology has been discussed in research sessions at the IEEE and the ASE over the past several years. However, more research is needed to show the prognostic value of the technology. Research to date shows it is possible that the swirling of blood can indicate less efficient flow, which may have implications in the development of heart failure, pulmonary hypertension and advancement of valvular disease. In the coronary arteries, research has shown there may be a connection between sheer stresses and disrupted blood flow in the formation of plaques on artery walls.
Companies that have developed echo blood flow dynamics imaging on their ultrasound systems to date include Hitachi, GE Healthcare, Fujifilm, Mindray and BK Medical.
Read more about this technology from ASE 2021 in the article Development of Echo Blood Flow Dynamics Imaging.
Related Dynamic Blood Flow Echo Imaging Content:
Aurora St. Luke’s Medical Center in Milwaukee Adopts Latest Echocardiography Imaging Software
A Glimpse Into the Future of Cardiac Ultrasound
Analogic Introduces New Premium Cardiac Imaging Software for bk3500 Ultrasound System
Improving Stent Designs With Computational Fluid Dynamics
VIDEO: Editor's Choice of Most Innovative New Cardiac Ultrasound Technology at ASE 2017
Cardiac Diagnostics View all 71 items
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at Cleveland Clinic, was the lead author on a followup study to the landmark WRAP-IT trial that showed the Tyrx bioresorbable antibacterial envelope was shown it significantly lower infection risk for patients who receive cardiac implantable electronic devices (CIED) and develop hematomas.[1]
The study results showed an 82% reduction in major infection among patients with hematoma in patients who had received the Tyrx. It is a antimicrobial envelope that is used to place implantable electrophysiology (EP) devices inside prior to closing the device pocket. While the envelope itself did not prevent hemotomas, as the rate was the same in the control group with out it, the Tyrx did lower infection rates in patients with hemotomas.
Read more in the article Tyrx Absorbable Antibacterial Envelope Effectively Reduces Infections in Cardiac Device Patients with Hematomas.
Reference:
One of the trends in cardiovascular information system (CVIS) and radiology PACS at the Healthcare Information Management Systems Society (HIMSS) 2021 conference was the deeper integration of third-party image analysis software and artificial intelligence (AI) into these systems. This eliminates software sitting on top of the CVIS or PACS, separate logins or needing to us a different screen or manually transferring information from the third-party app in into the final report.
A good example of this was Siemens Healthineers, which demonstrated a deep integration with Epsilon Imaging’s echocardiography strain imaging analysis software. The integration eliminates the need for a separate login to the software, and automated quantification and images are carried over directly into the syngo echo report.
Strain can be used to assess cardiac function more precisely than regular cardiac ultrasound exams. It has grown in its use for cardio-oncology programs, assessing a baseline cardiac function and the. Performing serial exams over the course of a cancer patient’s chemotherapy. Strain has seen growing interest and has been a hot topic the past couple years at the American Society of Echocardiography (ASE) meeting. Interest also has expanded greatly recently with reimbursement now available in the U.S.
Siemens said there also has been increased interest in strain this past year because it can show early indicators of cardiac issues in COVID-19 patients and can be used to help monitor COVID myocarditis patients.
Related Strain Echo and HIMSS Content:
VIDEO: An Overview of Echo Strain Imaging — Interview with Marielle Scherrer-Crosbie, M.D.
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
VIDEO: Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging — Interview with Federico Asch, M.D.
Assessing Cardiotoxicity Due to Cancer Therapy
Advances in CVIS and Enterprise iImaging at HIMSS 21
VIDEO: Cardiology AI Aggregates Patient Data and Enables Interactive Risk Assessments
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D., at HIMSS21
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D., at HIMSS21
The vendor MediCardia demonstrated smart software to aggregate cardiology patient data from numerous locations into one place at the 2021 Healthcare Information Management Systems Society (HIMSS) conference. This enables one dashboard view of the patient's relevant cardiac history, prior exams, imaging, ECGs, labs and procedures. It also uses artificial intelligence (AI) to pull key data elements about the patient to automatically create risk assessments based on current guidelines in a graphical format.
The interactive system also allows the cardiologist to adjust parameters in the patient risk score to immediately show the patient any impact on their score. This includes if they stopped smoking, began taking statins, etc. The dynamic graphics of the system are also designed to be more engaging with a patient during consultations, rather than plain white pages of reports.
MediCardia HeartChart is a cardiology-focused virtual care platform that serves as a unified and common interface for EHRs and remote technologies including wearables, consumer home medical devices, and implanted cardiac rhythm devices.
Related HIMSS CVIS and PACS Content:
Read about more advances in PACS and enterprise imaging at HIMSS 21.
VIDEO: Example of Epsilon Strain Imaging Deep Integration With Siemens CVIS
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D.
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D.
A new ultrasound imaging technology that may offer novel ways to diagnose and better understand cardiac diseases using dynamic blood flow imaging. This allows imaging of individual blood cells or contrast bubbles as they travel through the heart and vessels, showing detail in how the blood moves and swirls. These motions, including the formation of vortices, may offer new insight into different disease states and allow earlier diagnosis and a understand better when to intervene.
The examples shown in this short video are from Hitachi and GE Healthcare, both of which have highlighted this technology at the American Society of Echocardiography (ASE) annual meetings over the past four years.
Ultrasound vendors use different technology approaches, including vector flow imaging, particle imaging velocimetry and blood speckle tracking. All of them show small lines or arrows to indicate the direction the blood cells or bubbles are traveling, and color codes to indicate velocity. Some vendors offer quantification for some new measures of blood flow, but as of yet, there are no guidelines or standardized indexes as to what these numbers mean.
This technology has been discussed in research sessions at the IEEE and the ASE over the past several years. However, more research is needed to show the prognostic value of the technology. Research to date shows it is possible that the swirling of blood can indicate less efficient flow, which may have implications in the development of heart failure, pulmonary hypertension and advancement of valvular disease. In the coronary arteries, research has shown there may be a connection between sheer stresses and disrupted blood flow in the formation of plaques on artery walls.
Companies that have developed echo blood flow dynamics imaging on their ultrasound systems to date include Hitachi, GE Healthcare, Fujifilm, Mindray and BK Medical.
Read more about this technology from ASE 2021 in the article Development of Echo Blood Flow Dynamics Imaging.
Related Dynamic Blood Flow Echo Imaging Content:
Aurora St. Luke’s Medical Center in Milwaukee Adopts Latest Echocardiography Imaging Software
A Glimpse Into the Future of Cardiac Ultrasound
Analogic Introduces New Premium Cardiac Imaging Software for bk3500 Ultrasound System
Improving Stent Designs With Computational Fluid Dynamics
VIDEO: Editor's Choice of Most Innovative New Cardiac Ultrasound Technology at ASE 2017
EP Lab View all 81 items
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at Cleveland Clinic, was the lead author on a followup study to the landmark WRAP-IT trial that showed the Tyrx bioresorbable antibacterial envelope was shown it significantly lower infection risk for patients who receive cardiac implantable electronic devices (CIED) and develop hematomas.[1]
The study results showed an 82% reduction in major infection among patients with hematoma in patients who had received the Tyrx. It is a antimicrobial envelope that is used to place implantable electrophysiology (EP) devices inside prior to closing the device pocket. While the envelope itself did not prevent hemotomas, as the rate was the same in the control group with out it, the Tyrx did lower infection rates in patients with hemotomas.
Read more in the article Tyrx Absorbable Antibacterial Envelope Effectively Reduces Infections in Cardiac Device Patients with Hematomas.
Reference:
One of the trends in cardiovascular information system (CVIS) and radiology PACS at the Healthcare Information Management Systems Society (HIMSS) 2021 conference was the deeper integration of third-party image analysis software and artificial intelligence (AI) into these systems. This eliminates software sitting on top of the CVIS or PACS, separate logins or needing to us a different screen or manually transferring information from the third-party app in into the final report.
A good example of this was Siemens Healthineers, which demonstrated a deep integration with Epsilon Imaging’s echocardiography strain imaging analysis software. The integration eliminates the need for a separate login to the software, and automated quantification and images are carried over directly into the syngo echo report.
Strain can be used to assess cardiac function more precisely than regular cardiac ultrasound exams. It has grown in its use for cardio-oncology programs, assessing a baseline cardiac function and the. Performing serial exams over the course of a cancer patient’s chemotherapy. Strain has seen growing interest and has been a hot topic the past couple years at the American Society of Echocardiography (ASE) meeting. Interest also has expanded greatly recently with reimbursement now available in the U.S.
Siemens said there also has been increased interest in strain this past year because it can show early indicators of cardiac issues in COVID-19 patients and can be used to help monitor COVID myocarditis patients.
Related Strain Echo and HIMSS Content:
VIDEO: An Overview of Echo Strain Imaging — Interview with Marielle Scherrer-Crosbie, M.D.
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
VIDEO: Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging — Interview with Federico Asch, M.D.
Assessing Cardiotoxicity Due to Cancer Therapy
Advances in CVIS and Enterprise iImaging at HIMSS 21
VIDEO: Cardiology AI Aggregates Patient Data and Enables Interactive Risk Assessments
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D., at HIMSS21
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D., at HIMSS21
The vendor MediCardia demonstrated smart software to aggregate cardiology patient data from numerous locations into one place at the 2021 Healthcare Information Management Systems Society (HIMSS) conference. This enables one dashboard view of the patient's relevant cardiac history, prior exams, imaging, ECGs, labs and procedures. It also uses artificial intelligence (AI) to pull key data elements about the patient to automatically create risk assessments based on current guidelines in a graphical format.
The interactive system also allows the cardiologist to adjust parameters in the patient risk score to immediately show the patient any impact on their score. This includes if they stopped smoking, began taking statins, etc. The dynamic graphics of the system are also designed to be more engaging with a patient during consultations, rather than plain white pages of reports.
MediCardia HeartChart is a cardiology-focused virtual care platform that serves as a unified and common interface for EHRs and remote technologies including wearables, consumer home medical devices, and implanted cardiac rhythm devices.
Related HIMSS CVIS and PACS Content:
Read about more advances in PACS and enterprise imaging at HIMSS 21.
VIDEO: Example of Epsilon Strain Imaging Deep Integration With Siemens CVIS
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D.
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D.
A new ultrasound imaging technology that may offer novel ways to diagnose and better understand cardiac diseases using dynamic blood flow imaging. This allows imaging of individual blood cells or contrast bubbles as they travel through the heart and vessels, showing detail in how the blood moves and swirls. These motions, including the formation of vortices, may offer new insight into different disease states and allow earlier diagnosis and a understand better when to intervene.
The examples shown in this short video are from Hitachi and GE Healthcare, both of which have highlighted this technology at the American Society of Echocardiography (ASE) annual meetings over the past four years.
Ultrasound vendors use different technology approaches, including vector flow imaging, particle imaging velocimetry and blood speckle tracking. All of them show small lines or arrows to indicate the direction the blood cells or bubbles are traveling, and color codes to indicate velocity. Some vendors offer quantification for some new measures of blood flow, but as of yet, there are no guidelines or standardized indexes as to what these numbers mean.
This technology has been discussed in research sessions at the IEEE and the ASE over the past several years. However, more research is needed to show the prognostic value of the technology. Research to date shows it is possible that the swirling of blood can indicate less efficient flow, which may have implications in the development of heart failure, pulmonary hypertension and advancement of valvular disease. In the coronary arteries, research has shown there may be a connection between sheer stresses and disrupted blood flow in the formation of plaques on artery walls.
Companies that have developed echo blood flow dynamics imaging on their ultrasound systems to date include Hitachi, GE Healthcare, Fujifilm, Mindray and BK Medical.
Read more about this technology from ASE 2021 in the article Development of Echo Blood Flow Dynamics Imaging.
Related Dynamic Blood Flow Echo Imaging Content:
Aurora St. Luke’s Medical Center in Milwaukee Adopts Latest Echocardiography Imaging Software
A Glimpse Into the Future of Cardiac Ultrasound
Analogic Introduces New Premium Cardiac Imaging Software for bk3500 Ultrasound System
Improving Stent Designs With Computational Fluid Dynamics
VIDEO: Editor's Choice of Most Innovative New Cardiac Ultrasound Technology at ASE 2017
Information Technology View all 163 items
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at Cleveland Clinic, was the lead author on a followup study to the landmark WRAP-IT trial that showed the Tyrx bioresorbable antibacterial envelope was shown it significantly lower infection risk for patients who receive cardiac implantable electronic devices (CIED) and develop hematomas.[1]
The study results showed an 82% reduction in major infection among patients with hematoma in patients who had received the Tyrx. It is a antimicrobial envelope that is used to place implantable electrophysiology (EP) devices inside prior to closing the device pocket. While the envelope itself did not prevent hemotomas, as the rate was the same in the control group with out it, the Tyrx did lower infection rates in patients with hemotomas.
Read more in the article Tyrx Absorbable Antibacterial Envelope Effectively Reduces Infections in Cardiac Device Patients with Hematomas.
Reference:
One of the trends in cardiovascular information system (CVIS) and radiology PACS at the Healthcare Information Management Systems Society (HIMSS) 2021 conference was the deeper integration of third-party image analysis software and artificial intelligence (AI) into these systems. This eliminates software sitting on top of the CVIS or PACS, separate logins or needing to us a different screen or manually transferring information from the third-party app in into the final report.
A good example of this was Siemens Healthineers, which demonstrated a deep integration with Epsilon Imaging’s echocardiography strain imaging analysis software. The integration eliminates the need for a separate login to the software, and automated quantification and images are carried over directly into the syngo echo report.
Strain can be used to assess cardiac function more precisely than regular cardiac ultrasound exams. It has grown in its use for cardio-oncology programs, assessing a baseline cardiac function and the. Performing serial exams over the course of a cancer patient’s chemotherapy. Strain has seen growing interest and has been a hot topic the past couple years at the American Society of Echocardiography (ASE) meeting. Interest also has expanded greatly recently with reimbursement now available in the U.S.
Siemens said there also has been increased interest in strain this past year because it can show early indicators of cardiac issues in COVID-19 patients and can be used to help monitor COVID myocarditis patients.
Related Strain Echo and HIMSS Content:
VIDEO: An Overview of Echo Strain Imaging — Interview with Marielle Scherrer-Crosbie, M.D.
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
VIDEO: Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging — Interview with Federico Asch, M.D.
Assessing Cardiotoxicity Due to Cancer Therapy
Advances in CVIS and Enterprise iImaging at HIMSS 21
VIDEO: Cardiology AI Aggregates Patient Data and Enables Interactive Risk Assessments
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D., at HIMSS21
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D., at HIMSS21
The vendor MediCardia demonstrated smart software to aggregate cardiology patient data from numerous locations into one place at the 2021 Healthcare Information Management Systems Society (HIMSS) conference. This enables one dashboard view of the patient's relevant cardiac history, prior exams, imaging, ECGs, labs and procedures. It also uses artificial intelligence (AI) to pull key data elements about the patient to automatically create risk assessments based on current guidelines in a graphical format.
The interactive system also allows the cardiologist to adjust parameters in the patient risk score to immediately show the patient any impact on their score. This includes if they stopped smoking, began taking statins, etc. The dynamic graphics of the system are also designed to be more engaging with a patient during consultations, rather than plain white pages of reports.
MediCardia HeartChart is a cardiology-focused virtual care platform that serves as a unified and common interface for EHRs and remote technologies including wearables, consumer home medical devices, and implanted cardiac rhythm devices.
Related HIMSS CVIS and PACS Content:
Read about more advances in PACS and enterprise imaging at HIMSS 21.
VIDEO: Example of Epsilon Strain Imaging Deep Integration With Siemens CVIS
Photo Gallery of New Technologies at HIMSS 2021
VIDEO: Importance of Body Part Labeling in Enterprise Imaging — Interview with Alex Towbin, M.D.
VIDEO: Coordinating Followup for Radiology Incidental Findings — Interview with David Danhauer, M.D.
A new ultrasound imaging technology that may offer novel ways to diagnose and better understand cardiac diseases using dynamic blood flow imaging. This allows imaging of individual blood cells or contrast bubbles as they travel through the heart and vessels, showing detail in how the blood moves and swirls. These motions, including the formation of vortices, may offer new insight into different disease states and allow earlier diagnosis and a understand better when to intervene.
The examples shown in this short video are from Hitachi and GE Healthcare, both of which have highlighted this technology at the American Society of Echocardiography (ASE) annual meetings over the past four years.
Ultrasound vendors use different technology approaches, including vector flow imaging, particle imaging velocimetry and blood speckle tracking. All of them show small lines or arrows to indicate the direction the blood cells or bubbles are traveling, and color codes to indicate velocity. Some vendors offer quantification for some new measures of blood flow, but as of yet, there are no guidelines or standardized indexes as to what these numbers mean.
This technology has been discussed in research sessions at the IEEE and the ASE over the past several years. However, more research is needed to show the prognostic value of the technology. Research to date shows it is possible that the swirling of blood can indicate less efficient flow, which may have implications in the development of heart failure, pulmonary hypertension and advancement of valvular disease. In the coronary arteries, research has shown there may be a connection between sheer stresses and disrupted blood flow in the formation of plaques on artery walls.
Companies that have developed echo blood flow dynamics imaging on their ultrasound systems to date include Hitachi, GE Healthcare, Fujifilm, Mindray and BK Medical.
Read more about this technology from ASE 2021 in the article Development of Echo Blood Flow Dynamics Imaging.
Related Dynamic Blood Flow Echo Imaging Content:
Aurora St. Luke’s Medical Center in Milwaukee Adopts Latest Echocardiography Imaging Software
A Glimpse Into the Future of Cardiac Ultrasound
Analogic Introduces New Premium Cardiac Imaging Software for bk3500 Ultrasound System
Improving Stent Designs With Computational Fluid Dynamics
VIDEO: Editor's Choice of Most Innovative New Cardiac Ultrasound Technology at ASE 2017